bgb-16673
Generic: BTK Degrader BGB-16673·Code: BGB-16673
bgb-16673: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| BeOne Medicines Ltd. (ONC) | Phase 3 |
Clinical Trials (1)
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies
Frequently asked questions
Who is developing bgb-16673?
bgb-16673 is being developed by BeOne Medicines Ltd..
How many clinical trials involve bgb-16673?
BioSniper tracks 1 clinical trial involving bgb-16673.
Get deeper analysis on bgb-16673
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis